Tenax Therapeutics (NASDAQ: TENX) experienced a significant rally on Tuesday, closing up 27.84% at $2.37, following the disclosure of a substantial insider purchase. The stock's trading volume reached 12.16 million shares, approximately 3.2 times its recent daily average, indicating heightened investor interest.
According to a regulatory filing, ADAR1 Capital Management acquired 1,025,867 shares of Tenax over three days—August 20, 21, and 24—at a weighted average price of approximately $1.7684 per share, totaling about $1.81 million. The investor is listed as both a 10% owner and a director, not as an operating executive. Based on Tuesday's closing price, the value of this block has risen to roughly $2.43 million, representing an unrealized gain of about $617,000.
This insider buying comes on the heels of a dramatic decline in Tenax's stock price. On August 7, the shares closed at $13.44, but after the release of disappointing Phase 3 LEVEL trial results on August 10, the stock plummeted 89.8% to $1.375. Despite the recent surge, TENX still trades 82.4% below its August 7 close.
The LEVEL trial, which evaluated the company's lead candidate for pulmonary hypertension, failed to meet its primary endpoint of improving the six-minute walk distance. The trial also missed its principal secondary endpoint on symptom scores. However, a prespecified subgroup analysis of patients with baseline walk distance below the median showed an improvement of 26.3 meters compared to placebo, with a nominal p-value of 0.0112. Tenax cautioned that subgroup analyses are not sufficient to confirm efficacy.
In the overall population, the treatment demonstrated a 49% greater reduction in NT-proBNP, a biomarker of heart failure, and a 3.5 mmHg drop in right-ventricular systolic pressure compared to placebo. These secondary signals have provided some hope to investors, but the primary endpoint failure remains a fundamental concern.
Looking ahead, Tenax is scheduled to present late-breaking LEVEL trial findings at the European Society of Cardiology Congress on August 29 at 11:15 CEST. This presentation will be a critical catalyst for the stock, as investors will scrutinize the data for any signs of clinical benefit that could support regulatory submission.
The company's balance sheet appears robust, with cash holdings of $117.98 million at the end of June. This compares favorably to the company's current market capitalization of approximately $88.7 million, based on 37.42 million shares outstanding and Tuesday's closing price. However, the cash burn rate is accelerating; second-quarter research and development expenses climbed to $12.85 million, more than double the prior year's level, contributing to a net loss of $17.80 million.
Several analysts have revised their outlook on Tenax following the trial results. On August 11, Chardan downgraded the stock to Neutral from Buy, slashing its price target from $27 to $5. Canaccord Genuity reiterated a Buy rating but lowered its target from $35 to $4. Guggenheim maintained a Buy stance but cut its target from $40 to $4. Evercore ISI moved to In-Line from Outperform, reducing its target from $39 to $5. The lowest revised target of $4 still represents a 69% premium to Tuesday's closing price.
Despite the positive momentum from the insider purchase, significant risks remain. The missed primary endpoint is a major hurdle, and regulatory bodies may be reluctant to approve a filing based solely on subgroup analysis. Additional studies could further deplete the company's cash reserves, and the large share count increases dilution risk. Tuesday's rally reflects investor confidence in the company's strategic options, but the true test will come with the August 29 presentation and the upcoming FDA Type C meeting. Whether the company can convert this flexibility into a viable path forward remains to be seen.
